upsid upa new survey indic strong launch minim cannib
remain neutral rate share note see increment
posit feedback compani rheumatolog franchis base new survey
data indic strong expect upadacitinib launch pdufa date
specif contrast recent derm survey indic meaning skyrizi
cannib humira pso ra meaning project upa uptak appear
mainli impact lead jak pfe xeljanz humira appear rel
impervi combin feedback doc appear take jak-rel safeti
issu stride feel compel rais upa number ahead approv said
broader humira competit concern still place remain sidelin
rheumatologist survey indic ra market
highlight herein feedback partner spherix global insight recent survey
us rheumatologist indic rel stabl ra market humira
amgn enbrel still domin combin patient share declin slightli
hand newer agent like regn kevzara lly/inci olumi
upa look like could major categori disruptor pdufa
upadacitinib abbv oral inhibitor feedback particularli time
halo appear work fulli rheum indic earli
upa adopt sole connect moreov three-quart doc
expect use upa within launch ascrib patient share time notabl
doubl project olumi share constitut signific leap-frog
mayb importantli humira cannib project sharp contrast
derm feedback skyrizi uptak pso doc expect upa share come mainli
expens xeljanz share go current ra patient within
upadacitinib launch notabl project humira share flat scenario
take jak safeti issu stride recent xeljanz safeti disclosur around cv
risk mortal imbal higher dose somewhat surpris see
doc either neutral agre notion recent cv safeti concern
minim impact prescrib pattern
bottom line rais upa number ahead launch base feedback
think upa uptak faster previous model rais
estim leav humira unchang new
upa estim ahead consensu
respect vs factset
commerci regulatori clinic ip risk associ market pipelin product
fulli integr biopharmaceut compani
ep discount back
year
debt total capit
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
survey
remain neutral rate share note see increment posit
feedback compani rheumatolog franchis base new survey feedback indic
strong expect upadacitinib launch pdufa date august specif contrast
recent derm survey indic meaning skyrizi cannib humira pso
ra meaning project upa uptak appear mainli impact lead jak pfe xeljanz
humira appear rel impervi combin feedback doc appear
take jak-rel safeti issu stride feel compel rais upadacitinib number
ahead approv said broader humira competit concern still place remain
sidelin
partner spherix global insight survey high-volum us-bas rheumatologist
may elig particip survey rheumatologist must practic
year least ra patient manag spend least
profession time clinic practic see patient survey rheumatologist manag
averag ra patient mean ra patient captur survey
herein mostli focu feedback survey also supplement
select feedback survey field early/mid-februari note
discuss herein disclosur elev cv event mortal risk ra patient take high
xeljanz dose bid postmarket trial occur late-februari field
survey field survey
page
stabil name
game
past year ra brand share rel stabl see exhibit compar
last year olumi kevzara seen meaning increas share humira
continu captur one-quart share among biologic/jak treat patient
vs enbrel slip slightli share
even go back examin long-term trend see exhibit brand share
havent chang whole lot sinc humira green seen slight downtrend share
sinc captur one-quart market share enbrel bright blue see
similar trajectori time xeljanz red seen slight growth sinc captur
share kevzara pink grown slowli steadili sinc introduct
olumi orang quicker uptak remain earli launch
question consid ra patient treat biologics/jak pleas alloc percent patient follow brand total equal
question consid ra patient treat biologics/jak pleas alloc percent patient follow brand total equal
infliximab includ remicad inflectra infliximab includ remicad inflectra renflexi
page
rel stabil
assum new
brand share humira enbrel infliximab project erod next six month
respect see exhibit infliximab though
note histor eros project doc typic overst doc call
signific uptick olumi share current market share driven
part increas prescrib base doc six month kevzara
project see share increas similar magnitud prescrib base
grow next six month elsewher much shift market share
expect xeljanz project retain share actemra cimzia simponi
orencia rituxan respect
howev delv respons take consider
avail new agent upadacitinib includ treatment choic project share
xeljanz olumi look much differ
current month project brand share among biolog jak-inhibitor treat patient
question consid ra patient biologics/jak pleas alloc percent patient follow brand total equal
month ra patient treat biologics/jak anticip brand alloc refer current brand usag provid
page
one note infliximab ra trend overal shift away infliximab continu market
share prescrib base expect declin biosimilar impact present brand
remicad retain share infliximab market project drop
next six month lose ground pfizer inflectra current captur
infliximab share project increas merck renflexi share
expect reach consist prior survey feedback doc cite lack
insur requir primari barrier biosimilar brand uptak also hinder
gener shift away infliximab one-quart doc say theyr use less remicad
current month project infliximab share
remain top driver
brand choic
question indic anticip infliximab share month project ra patient treat
infliximab percent anticip brand percent anticip biosimilar
insur access continu top driver affect brand choic treatment ra see
exhibit follow specif moa mechan action overal fit patient
clinic profil howev found interest insur access appear
declin import treatment select process vs
may indic increas prescrib flexibl first-lin biologics/jak among payer trend
worth monitor go forward addit new agent like abbv upadacitinib come market
factor drive biologic/jak brand choic new initi
question think patient start biolog jak first time past year factor drove brand choic pleas alloc point across follow
categori alloc point influenti factor choic continu point alloc
page
doc awar
concern
appear take
stride
recal late-februari regul commun postmarket trial show
ra patient receiv xeljanz dose bid higher approv ra dose
bid qd xeljanz xr increas risk pulmonari embol death
patient treat anti-tnf xeljanz bid understand drove quit bit
investor concern impact jak classs market potenti survey field
three month safeti disclosur thu time gaug physician percept jak
safeti chang prescrib trend actual appear chang
meaning half respond awar xeljanz elev cardiovascular
risk without prompt major awar prompt indic news
rheum believ advers cardiovascular event like class effect jak
inhibitor limit xeljanz see exhibit rheumatologist appear cogniz
safeti risk elev limit high unapprov xeljanz dose bid two-third
agre approv bid xeljanz dose carri pe risk non-
approv bid dose gave similar feedback regard qd xeljanz dose importantli
close three-quart rheum indic limit impact prescrib trend ask
agre news heighten cv risk high dose xeljanz would minim impact
day-to-day prescrib ra doc agre anoth neutral exhibit
leav rheum disagre statement indic fact
impact day-to-day prescrib trend
close one-fifth say disclosur neg impact adopt newer
jak say neg impact adopt newer jak
question pleas rate level agreement follow statement use scale strongli disagre strongli agre
page
far away view top ra manufactur see exhibit consist
feedback derm see prior survey note ask manufactur provid
best servic support clinic practic fulli doc chose well ahead
respons favor roch close half
respond chose collabor manufactur came second
select respond manufactur best patient support program
came second come closer doc percept
commit clinic research vs percept service/support
rheumatolog commun vs knowledg sale rep
question compani biolog jak agent approv ra would say associ follow
page
translat
directli
stand benefit high esteem among rheumatologist upadacitinib launch
approach late summer one-third respond survey report
like earli adopt upadacitinib sinc manufactur see
exhibit interestingli view like relat abbv favor percept one-third
doc survey disagre statu third jak market signific
disadvantag context somewhat diverg feedback xeljanz first-jak-to-
market advantag survey feedback show close half respond view
xeljanz statu first jak market advantag olumi see exhibit
note increas survey doc view xeljanz first-to-market
statu advantag
question us fda approv upadacitinib treatment moder sever psoriasi next sever month soon
upadacitinib becom commerci avail anticip prescrib agent ra patient
question one thing olumi could bring market would make appeal use ra xeljanz much advantag think xeljanz statu
first jak market
page
half rheumatologist anticip start prescrib upadacitinib
within three month launch see exhibit includ doc wast time
wait prescrib expect start use upadacitinib within first month launch fulli
three-quart respond say theyll upadacitinib prescrib first six month
launch first year market refer olumi approv june
one year post-approv prescrib base survey doc
time upadacitinib adopt ra
question us fda approv upadacitinib treatment moder sever psoriasi next sever month soon
upadacitinib becom commerci avail anticip prescrib agent ra patient
page
good news
larg limit
jak humira
doc project avail upadacitinib immedi impact ra treatment
landscap expect captur market within first six month launch
would caution project doc classifi
least moder familiar upadacitinib think capabl grow doc familiar
pretti rapidli cours number unknown affect market dynam
upadacitinib launch price label access etc think valuabl examin
upadacitinib share expect come doc clearli expect much upadacitinib
use come approv jak inhibitor xeljanz olumi limit impact
upadacitinib avail doc say xeljanz share declin olumi growth
slow recal exhibit also reproduc exhibit without upadacitinib
market doc project xeljanz share would remain complet flat next six
month howev project six month share assum upadacitinib avail xeljanz
project lose market share declin share see exhibit
exhibit similarli doc project increas share olumi
without upadacitinib market see exhibit drop increas
assum upadacitinib commerci avail see exhibit exhibit
doc also expect slight increment share declin cimzia infliximab orencia simponi
upadacitinib avail
doc appear expect much cannib humira upadacitinib unlik skyrizi
impact psoriasi rheumatologist six-month humira share project without
upadacitinib avail essenti unchang assum upadacitinib
avail impli limit humira cannib part upa see exhibit also note
feedback enbrel similar came somewhat surpris us
recent psoriasi survey derm expect skyrizi captur signific share within
six-month launch share would come expens humira drive
import take-away feedback unlik skyrizi impact abbv derm
franchis doc expect upadacitinib launch net posit abbv rheumatolog
page
current month futur brand share among biolog jak-inhibitor treat patient assum avail
question consid ra patient biologics/jak pleas alloc percent patient follow brand total equal
upadacitinib becom commerci avail within next six month anticip six month project share chang
current futur brand share among biolog jak-inhibitor treat patient consid avail
note chart show data exhibit exhibit combin
question consid ra patient biologics/jak pleas alloc percent patient follow brand total equal
month ra patient treat biologics/jak anticip brand alloc refer current brand usag provid
upadacitinib becom commerci avail within next six month anticip six month project share chang doc
least moder familiar upadacitinib
page
expect lack
cannib
upa consist
prior feedback
support feedback doc zero xeljanz agent
signific risk olumi half rheumatologist indic xeljanz like
agent displac olumi introduct one-third expect olumi
would replac treatment proport doc believ agent
high risk displac low-singl digit humira remicad orencia iv
kevzara notabl doc gener see two jak inhibitor differenti
one-quart view clinic interchang ra
agent risk olumi launch
question product list agent olumi like replac practic pleas select one
total add due round
base feedback describ think upadacitinib uptak faster
previous model assum upa ww revenu year start
higher consensu respect
also see exhibit alter humira estim given feedback upa growth
larg come expens approv jak rather humira chang bring
ep estim slightli chang price target
ww upadacitinib estim consensu pjc
page
good sold
product sale
total revenu
sell gener administr
total revenu
statement oper
dollar except per share data
provis incom tax tax benefit
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
page
dollar except per share data
row revenu
elotuzumab revenu
total ww elotuzumab revenu
row profit share
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
